BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33359604)

  • 1. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
    Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
    J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
    Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
    Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
    Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
    Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM
    J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
    Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
    Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
    Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
    Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
    Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
    Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer.
    Gajendran C; Tantry SJ; M NS; Mohammed Z; Dewang P; Hallur M; Nair S; Vaithilingam K; Nagayya B; Rajagopal S; Sivanandhan D
    PLoS One; 2023; 18(1):e0279063. PubMed ID: 36595522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.